glp-1 prescriptions growth slowing 2024 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Agonists Weight Loss Drugs

10.1038/s41586-022-04431-8 83 MaidaA.LamontB

pmid:25261698 44

In this issue of Diabetologia , Hogan and colleagues report an improvement of psoriasis in three obese patients with type 2 diabetes several weeks after the initiation of therapy with the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists exenatide and liraglutide [2]

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8